PLIANT THERAPEUTICS, INC. Financing Cash Flow
PLIANT THERAPEUTICS, INC. (PLRX) reported Financing Cash Flow of $74.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $74.00K, a 85.14% decline year-over-year.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$32.27M, a 31734.31% decline year-over-year.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $72.00K, a 86.74% decline year-over-year.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was -$31.70M, a 237.12% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $23.12M, a 91.58% decline from fiscal 2023.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $274.40M, a 20.96% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $226.85M, a 8877.21% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $74.00K 10-Q · filed 2026-08-11 | -$32.19M derived: sum of 3 quarters · filed 2026-08-11 | -$32.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $74.00K 10-Q · filed 2026-05-11 | -$32.19M derived: sum of 2 quarters · filed 2026-05-11 | -$32.12M derived: sum of 3 quarters · filed 2026-05-11 | -$32.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$32.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$32.20M derived: sum of 2 quarters · filed 2026-03-11 | -$32.20M derived: sum of 3 quarters · filed 2026-08-11 | -$31.70M 10-K · filed 2026-03-11 |
| 2025-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $72.00K derived: sum of 2 quarters · filed 2026-08-11 | $570.00K 10-Q · filed 2025-11-06 | $672.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $498.00K 10-Q · filed 2026-08-11 | $600.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $498.00K 10-Q · filed 2026-05-11 | $600.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.14M derived: sum of 3 quarters · filed 2026-05-11 | $1.83M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $645.00K derived: sum of 2 quarters · filed 2026-03-11 | $1.33M derived: sum of 3 quarters · filed 2026-03-11 | $23.12M 10-K · filed 2026-03-11 |
| 2024-09-30 | $543.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.23M derived: sum of 2 quarters · filed 2025-11-06 | $23.02M 10-Q · filed 2025-11-06 | $23.23M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $684.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $22.47M 10-Q · filed 2025-08-07 | $22.69M derived: sum of 3 quarters · filed 2025-08-07 | $23.39M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $21.79M 10-Q · filed 2025-05-08 | $22.01M derived: sum of 2 quarters · filed 2025-05-08 | $22.71M derived: sum of 3 quarters · filed 2025-05-08 | $22.87M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $918.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.08M derived: sum of 3 quarters · filed 2025-03-03 | $274.40M 10-K · filed 2025-03-03 |
| 2023-09-30 | $699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $860.00K derived: sum of 2 quarters · filed 2024-11-07 | $274.19M 10-Q · filed 2024-11-07 | $274.47M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $273.49M 10-Q · filed 2024-08-07 | $273.77M derived: sum of 3 quarters · filed 2025-03-03 | $490.07M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $273.33M 10-Q · filed 2024-05-06 | $273.61M derived: sum of 2 quarters · filed 2025-03-03 | $489.91M derived: sum of 3 quarters · filed 2025-03-03 | $500.33M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $216.58M derived: sum of 2 quarters · filed 2025-03-03 | $227.01M derived: sum of 3 quarters · filed 2025-03-03 | $226.85M 10-K · filed 2025-03-03 |
| 2022-09-30 | $216.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $226.72M derived: sum of 2 quarters · filed 2023-11-09 | $226.57M 10-Q · filed 2023-11-09 | $227.09M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $10.27M 10-Q · filed 2023-08-09 | $10.79M derived: sum of 3 quarters · filed 2024-02-27 | $11.24M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$153.00K 10-Q · filed 2023-05-09 | $363.00K derived: sum of 2 quarters · filed 2024-02-27 | $812.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.00M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $516.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $965.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.16M derived: sum of 3 quarters · filed 2024-02-27 | $2.53M 10-K · filed 2024-02-27 |
| 2021-09-30 | $449.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $641.00K derived: sum of 2 quarters · filed 2022-11-08 | $2.01M 10-Q · filed 2022-11-08 | $2.25M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.56M 10-Q · filed 2022-08-08 | $1.80M derived: sum of 3 quarters · filed 2022-08-08 | -$566.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.37M 10-Q · filed 2022-05-09 | $1.61M derived: sum of 2 quarters · filed 2022-05-09 | -$758.00K derived: sum of 3 quarters · filed 2022-05-09 | $162.88M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$2.13M derived: sum of 2 quarters · filed 2022-03-01 | $161.51M derived: sum of 3 quarters · filed 2022-03-01 | $213.21M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $161.28M derived: sum of 2 quarters · filed 2021-11-09 | $212.97M 10-Q · filed 2021-11-09 | $259.81M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $163.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $215.34M 10-Q · filed 2021-08-09 | $262.17M derived: sum of 3 quarters · filed 2022-03-01 | $261.78M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $51.70M 10-Q · filed 2021-05-10 | $98.53M derived: sum of 2 quarters · filed 2022-03-01 | $98.14M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $46.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $46.44M derived: sum of 2 quarters · filed 2022-03-01 | $45.54M 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$1.29M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$898.00K 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |